Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Axsome Therapeutics, Inc. (AXSM) vs Caris Life Sciences,�Inc. (CAI)

Axsome Therapeutics, Inc. and Caris Life Sciences,�Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. is the larger, with a market value of $10.3B against $9.1B — 1.1× the size. Axsome Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 85.1×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 96.4% against 56.9%. Caris Life Sciences,�Inc. has the higher net margin (8.15% vs −24.7%) and the higher return on invested capital (50.0% vs 0.00%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 16 and Axsome Therapeutics, Inc. on 1.

Valuation

Metric AXSM CAI Biotechnology median
P/E n/m 85.08 7.88
P/S 13.01 9.14 11.47
P/B 121.31 15.29 2.52
Price to free cash flow n/m 72.98 21.16
EV/EBITDA n/m 48.03 0.74
EV/Sales 12.77 8.74 10.73
Earnings yield (1.92%) 1.18% (28.84%)
Free cash flow yield (0.71%) 1.37% (23.03%)

Profitability

Metric AXSM CAI Biotechnology median
Gross margin 93.24% 69.66% 65.16%
Operating margin (23.96%) 15.49% 0.00%
Net margin (24.68%) 8.15% 0.00%
Free cash flow margin (9.27%) 12.53% 0.00%
Return on equity (245.10%) 15.45% (57.72%)
Return on assets (27.35%) 7.39% (49.22%)
Return on invested capital 0.00% 49.95% 0.00%

Growth

Metric AXSM CAI Biotechnology median
Revenue growth (TTM) 56.87% 96.36% 5.64%
EPS growth (last fiscal year) 38.56% 59.45% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AXSM CAI Biotechnology median
Debt to equity 1.52 0.66 0.00
Current ratio 1.43 5.53 4.73
Net debt to EBITDA 1.29 (5.23) 0.96

Dividend

Metric AXSM CAI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric AXSM CAI Biotechnology median
Market cap 10.27b 9.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack